Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia
Shirai Y, Okugawa Y, Hishida A, Ogawa A, Okamoto K, Shintani M, Morimoto Y, Nishikawa R, Yokoe T, Tanaka K, Urata H, Toiyama Y, Inoue Y, Tanaka M, Mohri Y, Goel A, Kusunoki M, McMillan DC, Miki C
Scientific reports · 65 citas
Cómo se estudió
- Diseño
- Estudio de cohortes (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2017-06-30 · Sci Rep · vol. 7 · número 1 · pág. 4826
- Editorial
- Nature Portfolio
- Citado
- 83 citas · más que el 95% de estudios similares · 4.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 32 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Nutrition and Health in Aging · Frailty in Older Adults · GDF15 and Related Biomarkers
- Palabras clave
- Cachexia, Medicine, Fish oil, Gastrointestinal cancer, Chemotherapy, Bioelectrical impedance analysis, Cancer, Internal medicine, Lean body mass, Systemic inflammation, Gastroenterology, Eicosapentaenoic acid, Oncology, Inflammation, Polyunsaturated fatty acid, Colorectal cancer, Body mass index, Biology, Body weight, Fatty acid, Fish <Actinopterygii>
- MeSH
- humans, gastrointestinal neoplasms, inflammation, cachexia, dietary fats, unsaturated, eicosapentaenoic acid, fish oils, c-reactive protein, carcinoembryonic antigen, antineoplastic combined chemotherapy protocols, antigens, tumor-associated, carbohydrate, prognosis, survival analysis, cohort studies, body composition, nutritional status, aged, female, male, biomarkers, tumor
19 autores
- Yumiko Shirai
- Yoshinaga Okugawa🇯🇵🇺🇸 · autor de correspondenciaMie University; Baylor University Medical Center; Baylor Scott & White Research Institute
- Asahi Hishida🇯🇵Nagoya University
- Aki Ogawa
- Kyoko Okamoto
- Miki Shintani
- Yuki Morimoto
- Ryutaro Nishikawa
- Takeshi Yokoe
- Koji Tanaka
- Hisashi Urata
- Yuji Toiyama🇯🇵Mie University
- Yasuhiro Inoue🇯🇵Mie University
- Motoyoshi Tanaka
- Yasuhiko Mohri🇯🇵Mie University
- Ajay Goel🇺🇸Baylor University Medical Center; Baylor Medical Center at Garland; Baylor Scott & White Research Institute
- Masato Kusunoki🇯🇵Mie University
- Donald C. McMillan🇬🇧Glasgow Royal Infirmary; University of Glasgow
- Chikao Miki · autor de correspondencia
Resumen
El texto original del estudio, en el idioma en que se publicó.
Despite recent advances in chemotherapy for gastrointestinal cancer, a crucial factor related to poor prognosis is reduced tolerance to chemotherapy induced by cancer cachexia. Fish oil (FO)-derived eicosapentaenoic acid (EPA) modulates inflammation in patients with various malignancies; however, the impact of FO-enriched nutrition as a combined modality therapy on clinical outcomes remains controversial. We systemically analysed chronological changes in biochemical and physiological status using bioelectrical impedance analysis in 128 gastrointestinal cancer patients provided with or without FO-enriched nutrition during chemotherapy. Furthermore, we evaluated the clinical significance of FO-enriched nutrition and clarified appropriate patient groups that receive prognostic benefits from FO-enriched nutrition during treatment of gastrointestinal cancer. The control group showed significant up-regulation of serum CRP) levels and no significant difference in both skeletal muscle mass and lean body mass. In contrast, the FO-enriched nutrition group showed no changes in serum CRP concentration and significantly increased skeletal muscle mass and lean body mass over time. Furthermore, high CRP levels significantly correlated with reduced tolerance to chemotherapy, and FO-enriched nutrition improved chemotherapy tolerance and prognosis, particularly in gastrointestinal cancer patients with a modified Glasgow prognostic score (mGPS) of 1 or 2. We conclude that FO-enriched nutrition may improve the prognosis of patients with cancer cachexia and systemic inflammation (i.e., those with a mGPS of 1 or 2).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.